6-months of medically assisted glycemic improvementBariatric surgery
6-months of medically assisted glycemic improvement: Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
Bariatric surgery: Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
Study summary
The goal of this observational study is to assess if diabetes and obesity are independently related to functional and structural muscle deficits, and how muscular deficits relate to metabolic properties of diabetes and obesity. All studies will include clinical muscle strength and contractile examinations, functional tests, and MR imaging and spectroscopy techniques.
The main questions this project aims to answer are:
1. Is chronic hyperglycemia in type 1 and 2 diabetes associated with functional and structural deficits of skeletal muscles unrelated to the presence of neuropathy?
2. Is obesity associated with functional and structural impairments of skeletal muscles unrelated to the presence of type 2 diabetes ?
3. Does weight loss improve muscle metabolic flexibility and economy and modify skeletal muscle function and structure in obese subjects with and without type 2 diabetes?
The project will include three studies, intended to answer the hypotheses listed above:
Study 1: Evaluation of functional and structural muscular deficits of diabetic myopathy in relation to prolonged hyperglycemia prior to and 6 months following glycemic improvement in patients with type 1 and 2 diabetes
Study 2: Functional and structural muscular deficits in severely obese subjects with and without type 2 diabetes prior to assisted weight loss.
Study 3: Changes in functional and structural muscle properties following assisted weight loss in severely obese subjects with and without type 2 diabetes - a 1-year follow-up study.
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria:
Study 1:
* Age: 18-60 years
* BMI: 18.5 - 39, minimum weight = 50kg
* Chronic hyperglycemia: HbA1c of ≥ 70 mmol/mol with a duration of ≥ 2 months prior to enrollment
* Physical activity: Less than 3 x 60 min of structured physical activity per week
Study 2 \& 3:
* Age: 25-60 years
* BMI: ≥ 35
* Physical activity: Less than 3 x 60 min of structured physical activity per week
Healthy Control Participants:
* Age: 18-60 years
* BMI: 18.5 - 30, minimum weight = 50kg
* Physical activity: Less than 3 x 60 min of structured physical activity per week
Exclusion Criteria:
Study 1, 2, 3 and healthy controls:
* Diabetic neuropathy with expected motor deficits
* Uncontrolled cardiovascular or pulmonary disease, peripheral vascular disease, osteoarthropathy of the lower extremity, or any neurological og rheumatological disease which may affect muscle function, as well as any other disease that may effect ones ability to perform physical activity.
* Any Magnetic Resonance contraindications
* Any condition that by the principal investigator is expected to affect the participants ability to execute the study elements
Specifically for healthy control participants:
* The presence of diabetes or pre-diabetes (HbA1c ≥42 mmol/mol)
Primary outcome measure(s)
Baseline: Evaluating the presence of sarcopenia in relation to the presence of hyperglycemia and/or obesity — The prevalence of sarcopenia in participants with diabetes and hyperglycemia (study 1) or obesity (study 2) as compared to healthy control participants at baseline The presence of sarcopenia is assessed based on recommended methods including measures of muscle strength (Biodex Dynamometer), muscle quantity and quality (MRI), and physical performance tests.
Baseline: Skeletal muscle Force-velocity assessment in relation to the presence of hyperglycemia and/or obesity — The force-velocity relationship in participants with diabetes and hyperglycemia (study 1) or obesity (study 2) as compared to healthy control participants at baseline Assessed by isokinetic knee-extension and dorsal flexion on a Biodex Dynamometer at increasing angular-velocities
Baseline: Assessment of skeletal muscle fatigue in relation to the presence of hyperglycemia and/or obesity — Fatigue in participants with diabetes and hyperglycemia (study 1) or obesity (study 2) as compared to healthy control participants at baseline Assessed by a fatiguing isotonic protocol for knee-extension and dorsal flexion on a Biodex Dynamometer including twitch-parameters of knee-extensors
Changes in skeletal muscle force-velocity relationship with weight-loss or glycemic improvement — Change from baseline to follow-up at an average of 6 months for study 1 and 12 months for study 3
Changes in skeletal muscle fatigue in relation to weight-loss or glycemic improvement — Change from baseline to follow-up at an average of 6 months for study 1 and 12 months for study 3
Changes in parameters defining sarcopenia in relation to weight-loss or glycemic improvement — Change from baseline to follow-up at an average of 6 months for study 1 and 12 months for study 3
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
